News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY), Novartis Corporation (NVS) Head-to-Head Eye Drug Results Confirmed for May 1


4/21/2011 8:18:59 AM

LONDON, April 20 (Reuters) - Results of a key study comparing Roche (ROG.VX) and Novartis's (NOVN.VX) eye treatment Lucentis with low doses of cancer drug Avastin will, as predicted, be presented at the ARVO medical meeting on May 1.

Read at Reuters

comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES